案件核心信息 - 罗森律师事务所提醒在2025年2月21日至2025年8月28日期间购买Telix Pharmaceuticals Ltd (NASDAQ: TLX) 证券的投资者 关于2026年1月9日的重要首席原告截止日期 [1] - 一项针对Telix的证券集体诉讼已经提起 投资者可能有权通过风险代理收费安排获得赔偿 而无需支付任何自付费用 [2][3] 诉讼指控详情 - 指控被告在整个集体诉讼期间做出了重大虚假和/或误导性陈述 和/或未能披露 [5] - 具体指控包括：被告严重夸大了Telix在前列腺癌治疗候选药物方面取得的进展 [5] - 被告严重夸大了Telix的供应链及合作伙伴的质量 [5] - 因此 被告关于Telix业务 运营和前景的陈述在所有相关时间均存在重大虚假和误导性 和/或缺乏合理依据 [5] - 诉讼称 当真实情况进入市场时 投资者遭受了损失 [5] 律师事务所背景 - 罗森律师事务所是一家全球投资者权益律师事务所 专注于证券集体诉讼和股东衍生诉讼 [4] - 该所曾达成针对中国公司的史上最大证券集体诉讼和解 [4] - 根据ISS Securities Class Action Services数据 该所2017年在证券集体诉讼和解数量上排名第一 自2013年以来每年均位列前四 [4] - 该所已为投资者追回数亿美元 仅在2019年就为投资者确保了超过4.38亿美元 [4] - 创始合伙人Laurence Rosen在2020年被law360评为“原告律师界巨人” 多名律师获得Lawdragon和Super Lawyers认可 [4]

集体诉讼事件概述 - 一家全国性原告律师事务所Berger Montague PC宣布，已代表在2025年2月21日至2025年8月28日期间购买Telix Pharmaceuticals Ltd证券的投资者，对该公司提起集体诉讼 [1] 公司业务与诉讼指控 - Telix Pharmaceuticals Ltd是一家总部位于澳大利亚墨尔本的生物制药公司，致力于开发诊断和治疗性放射性药物产品 [2] - 诉讼指控被告在集体诉讼期间做出了虚假或误导性陈述，和/或未能披露公司夸大了其前列腺癌治疗候选药物的进展，并夸大了其供应链及合作伙伴的质量 [3] - 据称，关于公司业务、运营和前景的陈述是虚假的、误导性的或缺乏合理依据的，当公司业务的真实状况被公开后，投资者遭受了重大损失 [3] 律师事务所背景 - 提起此次诉讼的Berger Montague律师事务所是美国一家专注于复杂民事诉讼、集体诉讼和大规模侵权诉讼的知名律所 [4] - 该律所在2025年仅审后判决的金额就超过24亿美元，并在超过55年的时间里，为客户及其代表的集体追回了超过500亿美元 [4]

NEW YORK, Dec. 23, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Telix Pharmaceuticals Ltd. ("Telix Pharmaceuticals Ltd." or the "Company") (NASDAQ: TLX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Telix Pharmaceuticals Ltd. investors who were adversely affected by alleged securities fraud between February 21, 2025 and August 28, 2025. Follow the link below to get more information and be contacted by a member of our team: https ...

集体诉讼通知概要 - 格罗斯律师事务所向在特定集体诉讼期内购买Telix Pharmaceuticals Ltd (NASDAQ: TLX)股票的股东发布通知 鼓励其联系该律所 探讨可能的首席原告任命事宜 [1] 诉讼指控内容 - 集体诉讼期定义为2025年2月21日至2025年8月28日 [3] - 指控称 被告在该期间内发布了重大虚假和/或误导性陈述 和/或未能披露以下信息 [3] - 具体指控包括 被告在关于前列腺癌治疗候选药物的进展方面存在重大夸大 [3] - 被告在关于公司供应链及合作伙伴的质量方面存在重大夸大 [3] - 因此 被告关于公司业务、运营和前景的陈述在所有相关时间点均存在重大虚假和误导性 和/或缺乏合理依据 [3] 后续步骤与截止日期 - 股东参与集体诉讼的注册截止日期为2026年1月9日 股东不应延迟注册 [4] - 一旦注册 股东将被纳入投资组合监控软件 以便在整个案件生命周期内获取状态更新 [4] - 寻求成为首席原告的截止日期为2026年1月9日 [4] - 参与本案对股东无任何成本或义务 [4]

Philadelphia, Pennsylvania--(Newsfile Corp. - December 22, 2025) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Telix Pharmaceuticals Ltd. (NASDAQ: TLX) ("Telix" or the "Company") on behalf of investors who purchased Telix securities during the period of February 21, 2025 through August 28, 2025 (the "Class Period").Investor Deadline: Investors who purchased Telix securities during the Class Period may, no later than January 9, 2026, seek to ...

NEW YORK, Dec. 22, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Telix Pharmaceuticals Ltd. (NASDAQ: TLX). Shareholders who purchased shares of TLX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/telix-pharmaceuticals-ltd-loss-submission-form/?id=180979&from=4 CLASS PERIO ...

MELBOURNE, Australia and INDIANAPOLIS, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today provides a precision medicine portfolio update in relation to: TLX591-CDx (Illuccix® in approved jurisdictions, 68Ga-PSMA-11): Positive data from Phase 3 study in Chinese patients provides the basis for near-term NDA submission in China.TLX101-CDx (Pixclara®1, 18F-floretyrosine), PET imaging candidate for glioma: Following collaborative interactions with the FDA, fina ...

NEW YORK--(BUSINESS WIRE)---- $TLX #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Telix Pharmaceuticals Limited ("Telix†or the "Company†) (NASDAQ: TLX). Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. On July 22, 2025, Telix Pharmaceuticals reve ...

NEW YORK, Dec. 21, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) between February 21, 2025 and August 28, 2025, both dates inclusive (the "Class Period"), of the important January 9, 2026 lead plaintiff deadline in the securities class action first filed by the Firm. So what: If you purchased Telix securities during the Class Period you may be entitled to compensation without payment of any out of po ...

NEW YORK, Dec. 20, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) between February 21, 2025 and August 28, 2025, both dates inclusive (the “Class Period”), of the important January 9, 2026 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased Telix securities during the Class Period you may be entitled to compensation without payment of any out o ...